🔗 Share this article

As America undertakes unprecedented changes to its vaccination guidelines, one figure has surfaced unexpectedly: Tracy Beth Høeg, a US-based physician and epidemiologist who first made her name by casting doubt on COVID-19 vaccinations during the global health crisis and has concentrated on potential deaths after COVID-19 immunization in her recent time at the FDA.

Scheduled Shifts to Pediatric Immunization Schedule

Health officials were set to unveil radical revisions to the pediatric vaccination calendar recently, aligning the US with Denmark’s vaccine program, sources say – a significant shift that would put the US at odds with many the international standard with insufficient data for benefit. The planned update has been postponed until the coming year.

In place of the director of the vaccine center, Dr. Høeg is set to speak at the gathering. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the center this calendar year.

A New Direction at the Agency

Høeg's temporary position might represent a strengthened alliance between the drug and biologics divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the FDA – and it signals a increased emphasis upon dismantling already-approved immunizations at the FDA.

Høeg has often pushed for ending certain childhood vaccine recommendations in the US so as to align more in line with Denmark, a society with comprehensive healthcare and a citizenry about the population of Wisconsin’s.

In her initial comments, she has continued to focus on vaccines – typically the purview of Dr. Prasad, director of the FDA’s CBER – as opposed to pharmaceutical oversight.

Questions Over Background

Høeg has no apparent experience in pharmaceutical research, regulation or management, which has been typical for previous heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the agency head and CBER since earlier this year.

“She appears not to have the necessary background” for running the drug-regulation department, said Jonathan Howard. “She has not conducted a scientific study. She has no expertise in leading a sizeable institution. She has no expertise in drug approvals.”

Former directors of the center would “be deeply familiar with legal statutes and the research of pharmaceutical innovation”, said a former acting FDA commissioner. “Objectively, she lacks the type of experience that former directors who led the center have had.”

This division has an immense range of responsibilities at the agency, the former commissioner stated.

“Many people just zeroes in on the novel medication approvals, but the generic program clears thousands of generic drugs. There is also a biologic copycat branch, OTC medication office and other areas, and each of these must be looked after,” Dr. Woodcock said. “The thing you neglect, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a substantial administrative aspect to the role, which manages in excess of 5,000 personnel. “It’s a massive administrative position, if you do it right,” the former official said.

Official Statement and Disputed Policies

When asked about concerns about Høeg’s qualifications and whether this selection represents increased cooperation among regulatory chiefs on immunizations, a spokesperson stated that the “concerns rely on incorrect premises”.

“Her experience matches the duties of her position,” the representative stated, citing the months Høeg spent counseling the FDA commissioner on “medication safety and approval science, including computational safety modeling and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s new expedited review system, a controversial one-day therapy clearance system that reportedly worried her preceding directors. “By what process are these medications being picked for this expedited pathway? Who is making the choices?” Dr. Howard said. “There is a lot of confidentiality occurring at the regulatory body right now.”

Overall, he remarked, “the FDA looks to be trending towards less stringent regulations of pharmaceuticals, except for immunizations.”

Documented History on Immunizations

With immunizations, Høeg has a clearer, if problematic, track record, some experts observe. She authored a research paper using unverified public submissions to determine the incidence of heart inflammation after Covid immunization. She counseled the Florida chief medical officer Joseph Ladapo, who allegedly have modified findings to indicate Covid vaccines are riskier than they are.

Part of her “wish list” for the new government included changing regulations for new vaccines and discontinuing “non-essential” immunizations, she stated following the vote on a online show. At the agency, Dr. Høeg has according to sources floated the idea of excluding young men from obtaining Covid vaccinations.

“She’s an all-around true believer who begins with her preconceived notions and tailors the evidence to retrofit the data in a extremely misleading, untruthful manner,” Howard stated.

Consolidating Power and a “Campaign of Retribution”

Høeg joined fellow dissenters, {like|